BioClinica ApS: Financial statements 2024
CVR: 41590939
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
BioClinica ApS (CVR 41590939) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -63,754 and a net result of DKK -73,479 compared with DKK -24,530 the year before. Equity in the 2024 report amounted to DKK -168,480.
- Gross Profit
- DKK -63,754
- Profit/Loss
- DKK -73,479
- Equity
- DKK -168,480
- Total Assets
- DKK 206,665
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -64 t. | -73 t. | -168 t. | - |
| 2023 | - | -19 t. | -25 t. | -95 t. | - |
| 2022 | - | -22 t. | -23 t. | -70 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of October 29, 2024, Timothy Alan Cobb is registered as director of BioClinica ApS.
BioClinica ApS has published its annual report for 2023. Gross profit came to DKK -19,274, and the net result was DKK -24,530.
As of June 12, 2024, Michael Richard Sandusky is registered as director of BioClinica ApS.
As of April 22, 2024, Daniel Scott Braem has stepped down as adm. dir. of BioClinica ApS.
About BioClinica ApS
BioClinica ApS was a Danish company of the type Anpartsselskab based in København K, founded in 2020. The company has been dissolved on 26 February 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. In 2024, the company reported a gross profit of DKK -63,754 and a net result of DKK -73,479 compared with DKK -24,530 the year before. Equity in the 2024 report amounted to DKK -168,480.